Differences in clinical outcomes, health care resource utilization and costs in heart failure patients according to left ventricular ejection fraction

Introduction and objectives The impact of left ventricular ejection fraction (LVEF) on health care resource utilization (HCRU) and cost in heart failure (HF) patients is not well known. We aimed to compare outcomes, HCRUs and costs according to LVEF groups. Methods Retrospective, observational study...

Descripción completa

Detalles Bibliográficos
Autores: López Azor, Juan Carlos, Delgado Jiménez, Juan Francisco, Vélez, Jorge, Rodríguez, Rocío, Solís, Jorge, Oro, Manuel del, Ortega, Carmen, Salguero Bodes, Rafael, Palacios, Beatriz, Vicent, Lourdes, Moreno Muñoz, Guillermo, Rosillo, Nicolás, Varela, Luis, Capel, Margarita, Arribas Ynsaurriaga, Fernando, Bernal, José L., Bueno Zamora, Héctor José
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/109820
Acceso en línea:https://hdl.handle.net/20.500.14352/109820
Access Level:acceso abierto
Palabra clave:616.12
Cardiología
3205.01 Cardiología
Descripción
Sumario:Introduction and objectives The impact of left ventricular ejection fraction (LVEF) on health care resource utilization (HCRU) and cost in heart failure (HF) patients is not well known. We aimed to compare outcomes, HCRUs and costs according to LVEF groups. Methods Retrospective, observational study of all patients with an emergency department (ED) visit or admission to a tertiary hospital in Spain 2018 with a primary HF diagnosis. We excluded patients with newly diagnosed heart failure. One-year clinical outcomes, costs and HCRUs were compared according to LVEF (reduced [HFrEF], mildly reduced [HFmrEF], and preserved [HFpEF]). Results Among 1287 patients with a primary diagnosis of HF in the ED, 365 (28.4%) were discharged to home (ED group), and 919 (71.4%) were hospitalized (hospital group [HG]). In total, 190 patients (14.7%) had HFrEF, 146 (11.4%) HFmrEF, and 951 (73.9%) HFpEF. The mean age was 80.1 ± 10.7 years; 57.1% were female. The median [interquartile range] of costs per patient/y was €1889 [259-6269] in the ED group and €5008 [2747-9589] in the HG (P < .001). Hospitalization rates were higher in patients with HFrEF in the ED group. The median costs of HFrEF per patient/y were higher in patients in both groups: €4763 [2076-17 155] vs €3900 [590-8013] for HFmrEF vs €3812 [259-5486] for HFpEF in the ED group, and €6321 [3335-796] vs €6170 [3189-10484] vs €4636 [2609-8977], respectively, in the hospital group (all P < .001). This difference was driven by the more frequent admission to intensive care units, and greater use of diagnostic and therapeutic tests among HFrEF patients. Conclusions In HF, LVEF significantly impacts costs and HCRU. Costs were higher in patients with HFrEF, especially those requiring hospitalization, than in those with HFpEF.